Multicentre, retrospective cohort study with multivariable Cox proportional-hazards modelling and survival-time inverse-probability-weighting, evaluating the impact of different treatments on survival of proven COVID-19 patients admitted to two Hospitals in the province of Piacenza, Italy. Use of tocilizumab and of high doses of low molecular weight heparin, but not of antivirals (either alone or in combination), azithromycin, and any corticosteroid, was independently associated with lower mortality. Our results support further clinical evaluation of high doses of low molecular weight heparin and tocilizumab as COVID-19 therapeutics.
All Keywords
【저자키워드】 viral infection, Epidemiology, 【초록키워드】 Corticosteroid, Treatment, High dose, Azithromycin, Antiviral, Tocilizumab, Italy, heparin, COVID-19 therapeutics, survival, clinical evaluation, multicentre, Combination, COVID-19 patient, low molecular weight, Support, low molecular weight heparin, retrospective cohort study, lower mortality, multivariable, 【제목키워드】 cohort study,
【저자키워드】 viral infection, Epidemiology, 【초록키워드】 Corticosteroid, Treatment, High dose, Azithromycin, Antiviral, Tocilizumab, Italy, heparin, COVID-19 therapeutics, survival, clinical evaluation, multicentre, Combination, COVID-19 patient, low molecular weight, Support, low molecular weight heparin, retrospective cohort study, lower mortality, multivariable, 【제목키워드】 cohort study,
다변수 Cox 비례 위험 모델링 및 생존 시간 역확률 가중치를 사용한 다기관, 후향적 코호트 연구, 이탈리아 Piacenza 지방의 두 병원에 입원한 입증된 COVID-19 환자의 생존에 대한 다양한 치료법의 영향을 평가합니다. 토실리주맙과 고용량의 저분자량 헤파린을 사용하지만 항바이러스제(단독 또는 병용), 아지트로마이신 및 모든 코르티코스테로이드는 사용하지 않는 경우 독립적으로 낮은 사망률과 관련이 있습니다. 우리의 결과는 COVID-19 치료제로서 저분자량 헤파린과 토실리주맙의 고용량에 대한 추가 임상 평가를 뒷받침합니다.